United States - English - NLM (National Library of Medicine)

remedyrepack inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.   limitations of use: • use only if a clear diagnosis of migraine headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks. • sumatriptan tablets are not indicated for the prevention of migraine attacks. • safety and effectiveness of sumatriptan tablets have not been established for cluster headache. sumatriptan tablets are contraindicated in patients with: • ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions ( 5.1 )] • wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.   limitations of use: • use only if a clear diagnosis of migraine headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks. • sumatriptan tablets are not indicated for the prevention of migraine attacks. • safety and effectiveness of sumatriptan tablets have not been established for cluster headache. sumatriptan tablets are contraindicated in patients with: • ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions ( 5.1 )] • wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (

United States - English - NLM (National Library of Medicine)

auromedics pharma llc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 6 mg in 0.5 ml - sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: - use only if a clear diagnosis of migraine or cluster headache has been established. if a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, reconsider the diagnosis before sumatriptan injection is administered to treat any subsequent attacks. - sumatriptan injection is not indicated for the prevention of migraine or cluster headache attacks. sumatriptan injection is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)]. - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)]. -

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 6 mg in 0.5 ml - sumatriptan injection, usp is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: - use only if a clear diagnosis of migraine or cluster headache has been established. if a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, usp, reconsider the diagnosis before sumatriptan injection, usp is administered to treat any subsequent attacks. - sumatriptan injection, usp is not indicated for the prevention of migraine or cluster headache attacks. sumatriptan injection is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)] . - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precau

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 25 mg

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications ). safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. sumatriptan tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptane tablets. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort, vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. cerebrovascular syndromes include, but are not

United States - English - NLM (National Library of Medicine)

puretek corporation - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 50 mg - sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications ). safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. sumatriptan tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptane tablets. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort, vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. cerebrovascular syndromes include, but are not

United States - English - NLM (National Library of Medicine)

rebel distributors corp - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo), naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - sumatriptan succinate 85 mg - treximet is indicated for the acute treatment of migraine attacks with or without aura in adults. carefully consider the potential benefits and risks of treximet and other treatment options when deciding to use treximet. treximet is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of treximet have not been established for cluster headache. treximet should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive treximet, nor should patients who have had coronary artery bypass graft (cabg) surgery. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina, such as the prinzmetal variant), all forms of myocardial infarction, and silent

United States - English - NLM (National Library of Medicine)

tmig inc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 50 mg - sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications ). safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. sumatriptan tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptane tablets. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort, vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. cerebrovascular syndromes include, but are not

United States - English - NLM (National Library of Medicine)

proficient rx lp - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 25 mg - sumatriptan tablets, usp are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: sumatriptan tablets are contraindicated in patients with: teratogenic effects pregnancy category c: there are no adequate and well-controlled trials in pregnant women. in developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality. when administered by the intravenous route to pregnant rabbits, sumatriptan was embryolethal. sumatriptan tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of sumatriptan to pregnant rats during the period of organogenesis resulted in an increased incidence of fetal blood vessel (cervicothoracic and umbilical) abnormalities. the highest no-effect dose for embryofetal developmental toxicity in rats was 60 mg/kg/day, or approximately 3 times the maximum re